Closures, disposals reshaping the global petrochemical sector
The European Union is being hit the hardest by the rationalisation, while the United States and the Middle East are considered relatively immune. Petrochemical makers in Asia are also reducing capacity but at a slower pace compared with the EU.
Here is a list of some of the major closures, divestment and portfolio reviews:
** U.S.-based LyondellBasell (LYB.N), opens new tab in June said it had started exclusive talks to sell four olefin and polyolefin plants in Europe to Munich-based investment firm AEQUITA.
The sites to be sold are in France, Germany, Britain and Spain. The company has also said it is evaluating options for its factories in the Netherlands and Italy.
** U.S. chemical giant Dow Inc (DOW.N), opens new tab said at the beginning of July it would shut down three upstream sites in Europe: an ethylene cracker in Böhlen, Germany and chlor-alkali & vinyl assets in Schkopau, Germany, and its siloxanes plant in Barry, Britain. The company also announced in January that it would idle a cracker in the Netherlands.
** U.S. oil major ExxonMobil (XOM.N), opens new tab said last year it would shut down the steam cracker and close chemical production at Gravenchon in France, adding that the site had lost more than 500 million euros ($582.75 million) since 2018 and remains uncompetitive.
** British oil company Shell (SHEL.L), opens new tab in April completed the sale of its energy and chemicals park in Singapore, which includes a refinery, an ethylene cracker and other petrochemical assets.
The group's top executives told a post-results conference call in May that the group was undertaking a review of its chemical business, including in Europe. Shell hired Morgan Stanley to conduct the strategic review of its chemicals operations in Europe and the United States, the Wall Street Journal reported in March, citing sources.
** BP (BP.L), opens new tab said in February it was looking for potential buyers for its Ruhr Oel refinery, cracker and downstream assets at Gelsenkirchen in Germany.
** French oil major TotalEnergies (TTEF.PA), opens new tab said in April it would shut its oldest steam cracker in Antwerp, Belgium, by end-2027, citing a "significant surplus of ethylene expected in Europe".
** Eni (ENI.MI), opens new tab will complete the closure of Italy's two last steam crackers by the end of this year. One is in Brindisi, Apulia, and the second in Priolo, Sicily. It also closed a polyethylene plant in Ragusa, Sicily.
** Poland's Orlen (PKN.WA), opens new tab said at the end of 2024 it would scale back plans for its olefins petrochemical project, pushing back output until at least 2030 and aiming to cut its estimated cost by as much as a third.
** U.S. chemical group Huntsman Corp (HUN.N), opens new tab announced the closure of its polyurethanes facility in Deggendorf, Germany, and the reduction of some of its other sites and facilities around Europe.
The company will close a facility located in Moers, Germany. The closure is expected to be complete by the end of the current quarter.
** Japan's largest oil refiner, Eneos (5020.T), opens new tab, said in February that it would consider partially halting an ethylene production facility at its Kawasaki refinery at the end of 2027 due to falling demand. It said in March that it would gradually halt production of lubricants and some petroleum products at its Yokohama plant near Tokyo by March 2028, but will consider relocating lubricants' output to other facilities.
** Saudi Petrochemical Group SABIC said last year it planned to permanently shut one of its two naphtha-fed crackers at its plant in Geleen, the Netherlands.
($1 = 0.8580 euros)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
14 minutes ago
- Telegraph
Switzerland scrambles after Trump makes it Europe's biggest loser
For more than 200 years, Switzerland's approach to foreign policy has been to stay neutral. Yet when it comes to Donald Trump, a man who demands loyalty, neutrality doesn't get you much. The peace-loving Alpine nation has found itself at the forefront of Trump's erratic trade war, with exports such as Swiss chocolate and watches now subject to US tariffs of 39pc. 'Basically, we are all shocked,' says Jan Atteslander from Economiesuisse, a business lobby organisation representing 100,000 businesses in the country. 'We are one of the most open economic partners of the US. We have no tariff and non-tariff barriers for US goods or services. We are number six for foreign direct [investment] in the US. 'In this context, to find early on Friday, at 3am, that you are among the four countries that have – by way out now – the highest import tariffs in the US across the board, it's really a shock.' The outcome could hardly be worse: Only Syria, Laos and Myanmar face steeper rates than Switzerland of up to 41pc. Even Taliban-run Afghanistan was handed a more favourable deal of 15pc. To add insult to injury, the announcement came on Switzerland's National Day. 'There are two days in the year – one is Christmas, and the other one is Aug 1 – where normal people are on holiday,' shrugs Atteslander. The tariff shock has left Bern scrambling. Karin Keller-Sutter, the Swiss president, and Guy Parmelin, the economy minister, are flying to the US on Tuesday for crisis talks. It comes after a disastrous last-ditch call between the Swiss leader and Trump late on Thursday. The unexpected tariff blow has unleashed anger and soul-searching in Switzerland, with the tabloid Blick declaring it the country's greatest defeat since a battle against France in 1515, which ushered in its policy of international neutrality. 'We're joining the Canadians in protest against the US,' says Nikolay Markov, an economist at Pictet Asset Management in Geneva. He argues that the Swiss shouldn't have been caught flat-footed. 'It shouldn't be surprising because Switzerland has a significant trade surplus with the US. That's one of the reasons why Switzerland is on the monitoring watch list of the US treasury,' he says. Switzerland sold £28.8bn more goods to the US last year than it bought, with £47.6bn-worth of items heading to America. Exports range from luxury watches to precision instruments such as pneumatic screwdrivers and micrometres to medicines and Nespresso pods. Its trade surplus with the world's largest economy grew by 56.1pc from 2023. Trump initially subjected Switzerland to import duties of 31pc on 'liberation day' on April 2. Most goods exports, apart from pharmaceuticals and gold, will be subject to the new tariff from Thursday unless Keller-Sutter can strike a better deal. The US president has demanded that Swiss drugmakers lower their prices, an issue that may well come up in negotiations. Swiss business leaders and politicians are, for now trying to keep cool heads, hoping that this will be another example of the phenomenon that traders refer to as 'Taco': Trump always chickens out. While the president likes to announce large headline rates, he tends to use them as a bludgeon to negotiate better deals rather than following through. The stakes are high. Markov says he initially expected tariffs to shave 0.2pc of the Swiss economy's growth. 'Now it's 1.8pc, so it implies no growth for Switzerland in the coming year. It really changes the economic outlook – potentially materially,' he says. Such a knock to growth would plunge Switzerland into a technical recession and leave many workers unemployed. Chocolatiers are among those bracing for the impact. 'It's quite a shock because with tariffs at that level, it will be hard to serve the US market,' says Roger Wehrli. He is the Bern-based chief executive of Chocosuisse and Biscosuisse, trade bodies representing chocolatiers and confectionery makers. 'Combined with the exchange rate changes, this leads to an increase of costs in certain US markets by around 55pc compared to the beginning of the year,' he says. He warns that Switzerland being singled out leaves it particularly vulnerable. 'The UK has only a tariff of 10pc, the European Union 15pc. So our companies will have a comparative disadvantage. This leads to the conclusion that if this tariff remains, a lot of companies will pull out of the US market,' Wehrli says. The 39pc rate is beyond even the worst-case scenarios companies had planned for, Wehrli says. He also fears the wider damage to the Swiss economy. 'When we look at this economy in general, we export around 15pc to the United States. I'm very much concerned. It will pose severe challenges to the labour market.' Atteslander at trade body Economiesuisse says: 'There are thousands of jobs at risk, but I can't really tell if it is really going to happen or not.' For now, companies like Swatch are temporarily able to rely on all of the stock they rushed into the US in the first half of the year. The watchmaker has enough sitting in US warehouses to last it for at least three to six months, according to its chief executive. Knife maker Victorinox, another Swiss brand, meanwhile, said it was looking to make its operations more efficient through automation and 'collaborative solutions with our distribution partners'. 'This is not the first big challenge these export companies have faced over the last 15 to 20 years,' says Atteslander. If 39pc tariffs do remain in place, companies could explore workarounds. One unlikely benefactor of Trump's trade offensive could be Slovenia, according to Markov, the economist in Geneva. 'Slovenia is a major trading partner and is part of the European Union and the eurozone, so they're subject to 15pc tariffs. Switzerland could, to some extent, bypass the 39pc tariffs by exporting to Slovenia for re-exports to the US.' Swiss pharmaceuticals have already invested billions into production facilities in the small central European nation. Other industries could follow. Ultimately, though, Swiss leaders will be hoping to avoid all that. The federal council – the country's governing cabinet – on Monday said Switzerland was prepared to make a 'more attractive offer' to Trump in an effort to negotiate lower tariffs.
Reuters
14 minutes ago
- Reuters
European Q2 corporate profit outlook improves after U.S. trade deal
Aug 5 (Reuters) - The outlook for European corporate health has further improved, the latest earnings forecasts showed on Tuesday, after the European Union struck a framework trade deal with the U.S. a little more than a week ago. European companies are expected to report average growth of 3.1% in second-quarter earnings, LSEG I/B/E/S data shows. That is an increase from the 1.8% rise analysts had expected a week ago. Before the tariff deal, earnings had been expected to fall 0.3% in the quarter. This earnings season is the first to expose the impact of U.S. President Donald Trump's tariff-fueled trade war on corporate health. From last week, revenue is also expected to increase, the LSEG report showed. Analysts now expect a 2.0% fall, compared with a 3.3% drop expected before. It compares with a 3.0% increase in earnings and a 0.8% drop in revenues a year ago. After the EU agreement, Trump last Friday slapped new import tariffs on other countries, including a much higher 39% on EU-neighbour Switzerland. The framework trade agreement with the EU, which sets out a 15% import tariff, will apply broadly to EU goods from next month. But the trading bloc is still waiting on executive orders that would bring down the tariff on some products, a senior EU official said on Tuesday. The deal compares to a 30% tariff Trump had threatened to apply earlier in July. Before the agreement, U.S. President Trump's tariff policies have changed frequently since April, the most common start of the second fiscal quarter. Some were imposed while others were proposed and then delayed. German logistics giant DHL ( opens new tab on Tuesday confirmed its 2025 core profit expectations, opting to exclude potential tariff or trade policy impacts. Continental ( opens new tab meanwhile said on Tuesday that it suffered a net impact in a mid-double-digit million euro range from Trump's tariffs. Companies still to report this week include Novo Nordisk ( opens new tab, Commerzbank ( opens new tab, and Bayer ( opens new tab. As of Monday's close, the STOXX 600 was up about 7% year to date. ($1 = 0.8545 euros)
Reuters
14 minutes ago
- Reuters
Hims & Hers falls as declining subscriber base weighs on revenue
Aug 5 (Reuters) - Shares of telehealth firm Hims & Hers (HIMS.N), opens new tab fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment as well as the sexual health business. Hims shifted to selling smaller, "personalized" dosages of Novo Nordisk's ( opens new tab popular weight-loss drug, Wegovy, after the U.S. Food and Drug Administration suspended sales of the drug's copies it had allowed during a period of drug shortage. The company recorded $190 million in GLP-1-related revenue, down around $40 million sequentially, as it also lost subscribers on its commercially available doses of Wegovy. Novo Nordisk ( opens new tab in June terminated its partnership with Hims over the company's marketing tactics and continued sales of Wegovy copies even after FDA's ban on such sales. Leerink Partners analysts flagged the GLP-1 revenue dip as expected. However, the market reaction was negative after the results, as investor expectations were elevated, due to a surge in shares this year. Hims' stock has more than doubled so far this year, while Denmark-listed shares of Novo have fallen over 50%. The brokerage called the softness in Hims' core business, which includes treatments for conditions related to sexual health, a negative surprise. Hims & Hers reported a decline in its subscribers for its sexual health business, which sells generic drugs for erectile dysfunction. Canaccord Genuity echoed a near-term caution for the company, but remained constructive on the longer-term growth potential, citing strong year-over-year gains in newer specialties such as dermatology, weight management, and daily-use sexual health solutions. Despite the stock's sharp post-earnings pullback, the brokerage called the move a potential buying opportunity. Hims shares are priced at 95.85 times the company's estimated earnings for the next 12 months, a common benchmark for valuing stocks.
